DFFN

Diffusion Pharmaceuticals Inc. [DFFN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

DFFN Stock Summary

In the News

DFFN Financial details

Company Rating
-
Market Cap
8.98M
Income
-8.36B
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
0.63
P/C
-
P/FCF
-0.65
Quick Ratio
10.24
Current Ratio
10.71
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.1K
EPS next Y
-
EPS next Q
-
EPS this Y
-39.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-154.81%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-53338%
ROE
-44779%
ROC
-2.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.139999-14.37
52W High
-
52W Low
-
RSI
50
Rel Volume
7.31
Avg Volume
47.81K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.76446
-
-
Volatility
1.4%, 1.4%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
AMZN
CMC.DE
NVD.DE
DHR-PB
VOO
Same Sector
CNW.DE
0HD2.L
PRED
FSTX
SMD.L
Check Those
BANF
GSPL.NS
PIN.L
0668.HK
002249.SZ
Similar Market Cap
VERB
CYXT
RHRX
HAPY
HLFE.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 47.81K
  • Market Capitalization 8.98M
  • Employee 13
  • CEO Dr. Robert J. Cobuzzi Jr., Ph.D.
  • Headquarters Charlottesville,VA,US
  • IPO Date 2008-05-23
  • Website https://www.diffusionpharma.com

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.